reports
Evolus Inc: 5 directors
Five Directors at Evolus Inc sold after exercising options/sold 60,276 shares at between 12.645USD and 12.929USD. The significance rating of the trade was 54/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the com...
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G....
Tonix Pharmaceuticals to Present at the Alliance Global Partners (A.G.P) Healthcare Company Showcase CHATHAM, N.J., May 15, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipeline of development candidates, announced today that Seth Lederman, M.D., Chief Executive Officer, will participate virtually in a fireside chat at A.G.P.’s Healthcare Company Showcase on Tuesday, May 21, 2024, at 9:00 a.m. ET. A live webcast of the presentation can be found . A replay of ...
Lifeway Foods Inc: 1 director
A director at Lifeway Foods Inc sold 15,000 shares at 27.017USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clear...
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and...
Tonix Pharmaceuticals Reports First Quarter 2024 Financial Results and Operational Highlights On track to submit NDA in the second half of 2024 for Tonmya™ for fibromyalgia; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning continues for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., May 13, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a fully-integrated biopharmaceutical company with marketed products and a pipe...
Americold Announces First Quarter 2024 Results
Americold Announces First Quarter 2024 Results Achieves Double Digit Services Margins and Raises Annual Guidance Fully Recovered Workforce Exceeds Pre-Covid Productivity ATLANTA, GA., May 09, 2024 (GLOBE NEWSWIRE) -- Americold Realty Trust, Inc. (NYSE: COLD) (the “Company”), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced financial and operating results for the first quarter ended March 31, 2024. George Chappelle, Chief Execut...
IFF Chief Financial and Business Transformation Officer Glenn Richter ...
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) today announced that Glenn Richter, IFF’s Chief Financial and Business Transformation Officer, plans to retire Dec. 31, 2024 after a three-year tenure with the company. A succession process has been initiated to evaluate internal and external candidates to succeed Richter as CFO. “During his time at IFF, Glenn has driven multiple actions to improve our balance sheet and position the company for financial success,” said Erik Fyrwald, IFF CEO. “We have benefited from his experience and commitment to transformation. Notably, the work he has led on por...
IFF Reports First Quarter 2024 Results
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) reported financial results for the first quarter ended March 31, 2024. First Quarter 2024 Consolidated Summary: Reported (GAAP) Adjusted (Non-GAAP)1 Sales Income Before Taxes EPS Operating EBITDA Operating EBITDA Margin EPS ex Amortization $2.9 B $115 M $0.23 $578 M 19.9% $1.13 Management Commentary "We have started the year well, with good results across the majority ...
IFF Declares Dividend for Second Quarter 2024
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) announced that its Board of Directors has declared a regular quarterly cash dividend of $0.40 per share of its common stock, payable on July 10, 2024 to shareholders of record as of June 21, 2024. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, scent, health and biosciences, science and creativity meet to create essential solutions for a better world – from global icons to unexpected innovations and experiences. With the beauty of art and the precision of science, we are an international collective of thinkers who partners ...
- Dave Nicoski
- Ross LaDuke
Vital Signs: Actionable charts
In this product we rank the most positive and negative domestic stocks, filter the symbols by market-cap and trading volume, and then divide the companies into sectors and groups. We then manually look through charts leadership/changes, bottoms-up/top-down ideas, short-term patterns that may have long-term significance, etc. We believe you will find this product valuable as significant price and relative moves begin in the daily charts.
PEP PEPSICO INC.
TXN TEXAS INSTRUMENTS INCORPORATED
TRMK TRUSTMARK CORPORATION
SWN SOUTHWESTERN ENERGY COMPANY
SMTC SEMTECH CORPORATION
SATS ECHOSTAR CORPORATION CLASS A
RRC RANGE RESOURCES CORPORATION
NFG NATIONAL FUEL GAS COMPANY
MDWD MEDIWOUND
LWAY LIFEWAY FOODS INC.
HAS HASBRO INC.
FBP FIRST BANCORP
EQT EQT CORPORATION
DECK DECKERS OUTDOOR CORPORATION
CRK COMSTOCK RESOURCES INC.
VIRT VIRTU FINANCIAL INC. CLASS A
SYF SYNCHRONY FINANCIAL
HRTG HERITAGE INSURANCE HOLDINGS INC.
BSX. BELO SUN MINING CORP.
ORN ORION GROUP HOLDINGS
ITGR INTEGER HOLDINGS CORPORATION
PE. PURE ENERGY MINERALS LTD
DESP DESPEGAR.COM CORP.
AMRX AMNEAL PHARMACEUTICALS INC. CLASS A
NTB BANK OF N.T. BUTTERFIELD & SON
COOP MR. COOPER GROUP INC.
KTB KONTOOR BRANDS
ALXO ALX ONCOLOGY HOLDINGS
PRDO PERDOCEO EDUCATION CORP
LRN STRIDE INC
PRG PROG HOLDINGS INC
VRT VERTIV HOLDINGS CO (A)
AMAL AMALGAMATED FINANCIAL CORP
CGEM CULLINAN ONCOLOGY INC
RANI RANI THERAPEUTICS HLDGS INC
CR CRANE CO NEW
BGC BGC GROUP INC
SOWG SOW GOOD INC COM
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showca...
Tonix Pharmaceuticals Announces Presentation at Planet MicroCap Showcase CHATHAM, N.J., April 24, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates, today announced that Seth Lederman, M.D., Chief Executive Officer, will present at the Planet MicroCap Showcase in Las Vegas, Nev. on May 1, 2024, at 8:00 a.m. PT (11:00 a.m. ET). The presentation will include data from the recently reported positive Phase 3 RESILIENT trial of Tonmya™ (also known as TNX...
IFF to Release First Quarter 2024 Results on May 6, 2024
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE:IFF) today announced that it will release its first quarter 2024 earnings results following the market close on Monday, May 6, 2024. The management team will host a live webcast on Tuesday, May 7, 2024 at 9:00 a.m. ET to discuss results and outlook with the investor community. Investors may access the live webcast and accompanying slide presentation on the Company's website at . For those unable to listen to the live webcast, a recorded version will be made available for replay. Welcome to IFF At IFF (NYSE: IFF), an industry leader in food, beverage, h...
Moody's affirms International Flavors & Fragrances' Baa3 rating; outlo...
Moody's Ratings (Moody's) affirmed International Flavors & Fragrances, Inc.'s ("IFF") Baa3 issuer rating, Baa3 senior unsecured debt rating and its Prime-3 (P-3) rating for commercial paper. The outlook was changed to stable from negative. The stabilization of the outlook follows the company's rec...
Americold Realty Trust, Inc. Sets Date for First Quarter 2024 Earnings...
Americold Realty Trust, Inc. Sets Date for First Quarter 2024 Earnings Release and Conference Call ATLANTA, GA., April 04, 2024 (GLOBE NEWSWIRE) -- Americold Realty Trust (NYSE: COLD), a global leader in temperature-controlled logistics, real estate, and value-added services focused on the ownership, operation, acquisition and development of temperature-controlled warehouses, today announced that the Company will release first quarter 2024 financial results after the market closes on Thursday, May 9, 2024. A conference call will be held on Thursday, May 9, 2024 at 5:00 p.m. Eastern Time. ...
IFF Completes Divestiture of Cosmetics Ingredients Business
NEW YORK--(BUSINESS WIRE)-- IFF (NYSE: IFF) today announced that it has completed the previously announced divestiture of its Cosmetic Ingredients business to Clariant, a sustainably focused specialty chemicals company. As a part of Clariant, the business will continue to deliver innovative ingredients for the cosmetic and personal care product portfolio. “At IFF, our strategic transformation is focused on bringing leading innovation to best serve target customers in our core businesses,” said IFF CEO Erik Fyrwald. “To do this, we are optimizing and streamlining our portfolio to drive simpli...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financ...
Tonix Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Operational Highlights Positive results from confirmatory Phase 3 RESILIENT study reported in December 2023 position Tonmya™ for fibromyalgia for NDA submission second half of 2024; pre-NDA meeting with FDA scheduled for second quarter 2024 Commercial planning underway, including go-to-market, supply chain and manufacturing strategies, for U.S. launch of Tonmya, a potential new first-line, centrally-acting, non-opioid analgesic for the management of fibromyalgia CHATHAM, N.J., April 01, 2024 (GLOBE NEW...
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Dir...
Tonix Pharmaceuticals Announces Pricing of $4.4 Million Registered Direct Offering CHATHAM, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (“Tonix” or the “Company”), a biopharmaceutical company, today announced it has entered into a securities purchase agreement with existing healthcare focused institutional investors of the Company for the purchase and sale of 14,666,666 shares of its common stock (or common stock equivalents in lieu thereof) and warrants to purchase up to an aggregate of 14,666,666 shares of common stock in a registered dire...
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from...
Tonix Pharmaceuticals Receives Rare Pediatric Disease Designation from the FDA for TNX-2900 for the Treatment of Prader-Willi Syndrome TNX-2900 is a proprietary magnesium-potentiated formulation of intranasal oxytocin, a naturally occurring hormone that reduces appetite and eating Prader Willi syndrome is the most common genetic cause of life-threatening childhood obesity CHATHAM, N.J., March 25, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidat...
Tonix Pharmaceuticals Announces Poster Presentation Describing Discove...
Tonix Pharmaceuticals Announces Poster Presentation Describing Discovery of Novel Next-Generation Oxytocin Analogues at the American Chemistry Society (ACS) Spring 2024 Meeting Four Phase 2 investigator-initiated studies of TNX-1900 (intranasal potentiated oxytocin) are ongoing for pediatric obesity, binge eating disorder, bone health in autism and social anxiety disorder TNX-2900 (intranasal potentiated oxytocin) is being developed under an IND as a treatment for Prader-Willi Syndrome, an Orphan Disease characterized by excessive eating TNX-1900 and TNX-2900 may serve as novel n...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.